RhumbLine Advisers
ADMS

RhumbLine Advisers’s Adamas Pharmaceuticals ADMS Stock Holding History

RhumbLine Advisers’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-36,710
Closed -$106K – 3146
2020
Q1 		$106K Sell
36,710
-610
-2% -$2.73K ﹤0.01% 2768
2019
Q4 		$141K Buy
37,320
+154
+0.4% +$737 ﹤0.01% 2831
2019
Q3 		$190K Buy
37,166
+2,974
+9% +$18.4K ﹤0.01% 2762
2019
Q2 		$212K Buy
34,192
+5,084
+17% +$29.2K ﹤0.01% 2770
2019
Q1 		$207K Sell
29,108
-673
-2% -$6.05K ﹤0.01% 2738
2018
Q4 		$254K Buy
29,781
+9,514
+47% +$124K ﹤0.01% 2619
2018
Q3 		$406K Sell
20,267
-625
-3% -$14.7K ﹤0.01% 2364
2018
Q2 		$540K Buy
20,892
+5,525
+36% +$153K ﹤0.01% 2275
2018
Q1 		$367K Buy
15,367
+455
+3% +$14.3K ﹤0.01% 2352
2017
Q4 		$505K Sell
14,912
-2,441
-14% -$68.2K ﹤0.01% 2225
2017
Q3 		$367K Buy
17,353
+190
+1% +$3.48K ﹤0.01% 2468
2017
Q2 		$300K Sell
17,163
-2,309
-12% -$38.2K ﹤0.01% 2556
2017
Q1 		$341K Buy
19,472
+1,619
+9% +$27.6K ﹤0.01% 2441
2016
Q4 		$302K Sell
17,853
-140
-0.8% -$2.17K ﹤0.01% 2490
2016
Q3 		$295K Buy
17,993
+300
+2% +$4.56K ﹤0.01% 2492
2016
Q2 		$268K Sell
17,693
-394
-2% -$6.5K ﹤0.01% 2595
2016
Q1 		$262K Buy
18,087
+3,920
+28% +$66K ﹤0.01% 2602
2015
Q4 		$401K Buy
14,167
+530
+4% +$8.92K ﹤0.01% 2388
2015
Q3 		$228K Buy
13,637
+807
+6% +$18.4K ﹤0.01% 2711
2015
Q2 		$336K Buy
+12,830
New +$250K ﹤0.01% 2581

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

RhumbLine Advisers's ADMS Position: Q2 2020 in Review

RhumbLine Advisers sold out of Adamas Pharmaceuticals (ADMS) in Q2 2020, closing a stake of 36,710 shares — an estimated $106K sold.

RhumbLine Advisers first reported a position in ADMS in Q2 2015 and held it in 20 quarters. The position peaked at $540K in Q2 2018. 61 funds tracked by Wall St. Rank hold ADMS as of Q2 2020.

  • RhumbLine Advisers reported no remaining Adamas Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 36,710 Adamas Pharmaceuticals shares in Q2 2020, an estimated $106K.
  • RhumbLine Advisers first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 20 quarters.
  • RhumbLine Advisers's Adamas Pharmaceuticals position peaked at $540K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2020.

Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.